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We previously reported familial aggregation in flush re-
sponse to niacin skin patch among schizophrenia patients
and their nonpsychotic relatives. However, little is known
about whether this abnormal skin response is associated
with genetic loading for schizophrenia. This study com-
pared the niacin flush response in subjects from families
with only one member affected with schizophrenia (simplex
families) with those from families having a sib-pair with
schizophrenia (multiplex families). Subjects were patients
with schizophrenia and their nonpsychotic first-degree rel-
atives from simplex families (176 probands, 260 parents,
and 80 siblings) and multiplex families (311 probands, 180
parents, and 52 siblings) as well as 94 healthy controls.
Niacin patches of 3 concentrations (0.001M, 0.01M,
and 0.1M) were applied to forearm skin, and the flush re-
sponse was rated at 5, 10, and 15 minutes, respectively,
with a 4-point scale. More attenuated flush response to
topical niacin was shown in schizophrenia probands and
their relatives from multiplex families than in their coun-
terparts from simplex families, and the differentiation was
better revealed using 0.1M concentration of niacin than
0.01M or 0.001M. For the highest concentration of
0.1M and the longest time lag of 15 minutes, a subgroup
of probands (23%), parents (27%), and siblings (19%) still
exhibited nonflush response. Flush response to niacin skin
patch is more impaired in schizophrenia patients and their
relatives from families with higher genetic loading for
schizophrenia, and this finding has implications for future
genetic dissection of schizophrenia.
Key words: nicotinic acid/niacin skin test/prostaglandin/
vulnerability indicator
Introduction
Niacin (nicotinic acid), both a vitamin and a drug for hy-
perlipidemia,1 can induce a visible skin flush response
that is caused by prostaglandin-mediated cutaneous va-
sodilatation.2,3 The observation of reduced flush re-
sponse in patients with schizophrenia in early research
on high-dose niacin treatment4 had led to the proposal
of niacin challenge as a simple biochemical test for this
illness.5 Studies utilizing oral niacin6–8 or topical skin
patch of methyl nicotinate (a skin-permeable ester of nic-
otinic acid)9–15 consistently found attenuated flush re-
sponse in patients with schizophrenia. Depending on
the criteria to define niacin nonresponse, the prevalence
rates of attenuated or absent response to niacin skin
patch in patients with schizophrenia ranged from 49%
to 90%, compared with 8%–23% in healthy controls.9,11,16
The attenuated flush response to locally applied niacin
in schizophrenia patients, however, was not observed in
patients with depression,17 bipolar disorder,8,15,16 or au-
tism.18 The reduced niacin flush response in patients with
schizophrenia was not affected by medication status,10,19
antipsychotic drug doses,8,14,15 or substance use such as
cigarette smoking,10,12,15,16,20 coffee drinking,15 or alco-
hol consumption.10,15 Moreover, 2 previous studies
reported abnormal flush response to niacin skin patch
in first-degree relatives of schizophrenia patients,21,22
and our recent study showed familial aggregation in ni-
acin flush response among schizophrenia patients and
their nonpsychotic relatives, with the greatest estimated
heritability ranging from 47% to 54%.23 Thus, niacin
flush response appeared to be a potential marker of
genetic susceptibility to schizophrenia.
Schizophrenia is postulated to occur through a multi-
factorial process involving several genes with environ-
mental factors.24 To identify subgroups of patients
with greater etiological homogeneity, a familial-sporadic
approach was initially proposed by discriminating be-
tween patients with and without a family history.25
Because those lacking family history may still have
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genetic vulnerability, a continuum of more genetic to less
genetic variation in the etiology of schizophrenia was sug-
gested.26 This led to a similar approach but with more
stringent definition on familial/genetic cases by discrim-
inating between multiplex families (families having at
least 2 schizophrenia patients) and simplex families (fam-
ilies with only one member with schizophrenia). The util-
ity of this strategy has been demonstrated in detecting the
association of higher genetic loading with more severe
neuropsychological deficits, which are potential markers
for genetic susceptibility to schizophrenia, in nonpsy-
chotic relatives of schizophrenia patients.27–29
In this study, we aimed to compare the niacin flush re-
sponse of schizophrenia patients and their relatives with
that of healthy controls and to examine the effect of ge-
netic loading, assuming that subjects from families hav-
ing a sib-pair with schizophrenia (multiplex families)
have higher genetic loading for schizophrenia than those
from families without positive history in first-degree rel-
atives other than the proband (simplex families). We pre-
dicted that the skin response to niacin would be abnormal
in patients with schizophrenia and their relatives and that
the abnormalities would be more prominent in subjects
from multiplex families than in their counterparts from
simplex families.
Methods
Subjects
The present study recruited probands of simplex and
multiplex families as well as their nonpsychotic relatives
from 2 studies on schizophrenia. The first study recruited
specifically probands of simplex families from inpatient
or outpatient units at the Department of Psychiatry,
National Taiwan University Hospital, Taipei, and Ju
Shan Hospital, a private psychiatric hospital in Taoyuan
County, if they met the Diagnostic and Statistical Man-
ual of Mental Disorders, Fourth Edition (DSM-IV) cri-
teria for schizophrenia or schizoaffective disorder,
depressive type. Any family having 2 coaffected siblings
was not included for the study. Part of the recruited sub-
jects (153 probands, 217 nonpsychotic parents, and 70
nonpsychotic siblings) had participated in our previous
study.23 However, among them 2 families were found
to have one parent affected with schizophrenia and
were thus excluded from the subsequent analyses. Fur-
ther, any subject with mental retardation, dementia, or
prominent substance use problem was excluded, too.
For the final analysis, subjects from simplex families in-
cluded 176 schizophrenia probands, 260 unaffected
parents, and 80 unaffected siblings. Whether probands
or their first-degree relatives had schizophrenia was de-
termined by means of face-to-face interview or informa-
tion provided by directly interviewed relatives on those
who were not interviewed personally, and, among a total
of 849 alive first-degree relatives from simplex families,
420 (49.5%) were directly interviewed.
Subjects frommultiplex families constituted a subgroup
ofparticipants ina secondstudy, theTaiwanSchizophrenia
Linkage Study (TSLS), which has been described in detail
elsewhere.30 In brief, the TSLS was aimed at collecting
a large nation-wide sample of schizophrenia families with
at least 2 siblings fulfillingDSM-IV criteria for schizophre-
nia or schizoaffective disorder, depressive type, and
successfullyrecruited607families,comprising2490subjects
(1258 probands, 922 parents, and 310 unaffected siblings).
The initial researchprotocolof theTSLSdidnot includeni-
acin skinpatchtestuntil the lastyearof theproject, andthus
only 633 out of 2490 (25.4%) subjects (350 probands, 223
parents, and 60 unaffected siblings) were assessed with the
skin test. The subjects who undertook niacin skin test and
those who did not, regardless of probands, parents, or sib-
lings, were comparable in terms of age, gender ratio, and
years of education (all P > .05). For probands, there was
nodifferenceinageatonsetbetweenthosewhowereassessed
withniacin skin test and thosewhowere not (P> .05).After
excludingthosewithmentalretardation,dementia,orprom-
inent substance use problem, the final study subjects from
multiplex families consistedof 311 schizophrenia probands,
180 unaffected parents, and 52 unaffected siblings.
Healthy volunteers were recruited frommembers of the
hospital staff of National Taiwan University Hospital
who reported a negative history of any psychiatric disor-
der and constituted the control group. All participants in
this study, regardless of the multiplex, simplex, or control
group, were Taiwanese Han Chinese in ethnic origin and
had to meet the following criteria before undertaking ni-
acin skin patch test: no history of alcohol and drug abuse,
no pregnancy, no major systemic illness (especially heart
disease, allergic skin illness, and asthma), and no usage of
anti-inflammatory drugs (eg, aspirin, nonsteroidal anti-
inflammatory drugs, and steroids) within 3 days before
the niacin skin test. Subjects were included in the study
after they had given written informed consent to partic-
ipate, and the study was approved by the institutional re-
view boards of the participating hospitals.
Diagnostic Procedures
For both simplex and multiplex groups, all the schizo-
phrenia probands and their first-degree relatives were
interviewed with the Diagnostic Interview for Genetic
Studies (DIGS).31 Interrater reliability of the Chinese
version of the DIGS for the diagnoses of schizophrenia,
bipolar disorder, and major depression was reported to
be good, with the kappa values ranging from 0.86 to
0.93.32 The Chinese version of the Family Interview
forGenetic Studies (FIGS)33 was used by the interviewers
to obtain relevant family history information on those
relatives who were not directly interviewed for the study.
Interviewers were research assistants who had received
rigorous training on the Chinese version of the DIGS
S.-S. Chang et al.
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and the FIGS.30 Best-estimate final diagnosis according
to the DSM-IV criteria was made independently by 2
board-certified psychiatrists using all available informa-
tion, including the DIGS, the FIGS, the hospital records,
and the interviewers’ notes. When the 2 diagnostians dis-
agreed, a senior research psychiatrist (H-G.H.) would be
sought and a consensus in diagnosis was reached after
discussion.
All of the probands from both the multiplex and sim-
plex groups received the final diagnosis of schizophrenia
except 2 probands from multiplex families who were di-
agnosed as schizoaffective disorder, depressive type.
These 2 subjects and their relatives were included in
the following analyses because the study results remained
unchanged after excluding them. In addition, the DIGS
contains a section of the modified Structured Interview
for Schizotypy (SIS),34 which measures both schizotypal
symptoms and signs. Information obtained by the SIS
was used to diagnose DSM-IV schizotypal, paranoid,
and schizoid personality disorders in nonpsychotic rela-
tives.35 Among siblings from simplex families, 0 (0%),
0 (0%), and 1 (1.3%) subject was diagnosed as having
schizotypal, paranoid, and schizoid personality disorders,
respectively, and the corresponding figures among parents
from simplex families were 0 (0%), 4 (1.5%), and 1 (0.4%).
The study results remained unchanged when we treated
those with these personality disorders as affected cases
and accordingly reassigned their families to the multiplex
group (for an affected sibling) or excluded these families
from the subsequent analyses (for an affected parent).
Niacin Skin Test
We used a modified protocol that was based on Ward
et al.9 In the form of aqueous methyl nicotinate
(AMN), one drop of 0.001M, 0.01M, or 0.1M niacin so-
lution was put onto 3 patches of absorbent paper, respec-
tively. The concentration of 0.0001M evoked nearly no
flush response even in the healthy controls and thus
was not used in this study.16 Using adhesive tapes, the
3 AMN patches, as well as a blank one for negative con-
trol use, were applied to each subject’s forearm skin for 5
minutes and then removed. The following criteria with
a 4-point scale was used to rate the skin flush reaction
at 5, 10, and 15 minutes after application of the patches:
0 = no erythema, 1 = incomplete erythema, 2 = complete
erythema within the definite area of the patch, and 3 =
erythema plus edema beyond the definite area of the
patch. Focusing on lack of flush, we also treated the scor-
ing as binary using the cut-off point of 2 and categorized
score 0 or 1 as nonflush response.9,19
In a preliminary study of 50 subjects (34 patients with
schizophrenia, 4 patients with bipolar disorder, and 12
healthy controls), the interrater reliability for the flush
scoring by 2 psychiatrists (S-S.C. and C-M.L.) was shown
to be good with the intraclass correlation coefficients
ranging from 0.85 to 0.94 for different concentrations
of AMN.16 Five research assistants trained by the 2 psy-
chiatrists then assessed flush response for all subjects in
this study. In another preliminary evaluation of 50 sub-
jects (25 patients with schizophrenia and 25 healthy con-
trols), the interrater reliability of the 5 research assistants
was good, with the intraclass correlation coefficients for
the 3 different concentrations of AMN being 0.76 (95%
CI: 0.67, 0.84), 0.74 (95% CI: 0.65, 0.83), and 0.69 (95%
CI: 0.59, 0.79), respectively.
Data Analysis
Group comparisons in demographic features were con-
ducted using Student’s t test for continuous variables
and v2 or Fisher’s exact test (when the cell number
was less than 5) for categorical variables. Because familial
aggregation in niacin flush response had been demon-
strated in our prior work,23 a linear mixed-effects model
that allows for adjustment for intrafamilial correlation
was adopted.36 This model could also properly account
for correlation between repeated measurements on the
same subject,37 which, in the present study, included 9
flush scores rated at 3 time points (5, 10, and 15 minutes)
for 3 concentrations of AMN (0.1M, 0.01M, and
0.001M). Therefore, family, time, and concentration
were treated as random effects in the mixed-effects model
if indicated, and SAS PROC MIXED (SAS Institute,
Cary, NC) was used for the analyses.
For each of the comparisons between healthy controls
and probands, parents, or siblings, a multivariate linear
mixed-effects modeling analysis was conducted to exam-
ine the overall effects of group (multiplex, simplex, and
control), concentration, time, interactions (among group,
concentration, and time), and other covariates (age, gen-
der, cigarette smoking, coffee drinking, and history of
food or drug allergy). A P value of less than .05 was con-
sidered significant. If a 2-way interaction term involving
groupwas significant, groupdifferenceswith respect to in-
dividual levels of the other variable (ie, concentration or
time) were examined using either generalized linear mod-
eling or mixed-effects modeling analyses, as indicated, af-
ter adjustment for other covariates. The nominal value of
significancewas adjusted accordingly (P value of less than
.006, ie, .05 divided by 9). For any significant group effect,
post hoc pairwise comparisons among the 3 groups were
conducted with Bonferroni correction. Effect sizes in nia-
cin flush scores were calculated by subtracting the mean
values between the groups of interest and then divided
by the pooled SD, representing group differences in SDs.
Results
Sample Characteristics
Table 1 summarizes the demographic features of all study
subjects. Probands from multiplex and simplex families
were comparable in age of onset. The multiplex and
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simplex groups, regardless of probands, parents, or sib-
lings, did not differ in gender ratio, rate of coffee drink-
ing, and rate of allergy history (except for a lower rate in
probands frommultiplex families), whereas subjects from
multiplex families were older and had higher prevalence
rate of cigarette smoking than their counterparts from
simplex families. When the multiplex families were com-
pared with healthy controls, there were more males for
probands, the age was older, the smoking prevalence
was higher, whereas the prevalence of coffee drinking
was lower for all family members. Meanwhile, in compar-
ing the simplex families with healthy controls, the age was
younger and the smoking prevalence was higher for pro-
bands, the age was older and the rate of allergy history was
higher for parents, as well as the prevalence of coffee
drinking was lower for both probands and parents.
Table 2. Mixed-Effects Model Results of Niacin Flush Response in a Variety of 3-Group Comparisons.
Multiplex Probands (N = 311),
Simplex Probands (N = 176),
and Controls (N = 94)
Multiplex Parents (N = 180),
Simplex Parents (N = 260),
and Controls (N = 94)
Multiplex Siblings (N = 52),
Simplex Siblings (N = 80),
and Controls (N = 94)
Overall Effects F df P F df P F df P
Group 26.97 2 4705 <.0001 24.07 2 4340 <.0001 7.81 2 1776 .0004
Concentration 19.66 1 4705 <.0001 25.02 1 4340 <.0001 15.82 1 1776 <.0001
Time 7.13 1 4705 .008 8.98 1 4340 .003 5.30 1 1776 .02
Group-by-
concentration
132.87 2 4705 <.0001 137.75 2 4340 <.0001 32.20 2 1776 <.0001
Group-by-time 13.69 2 4705 <.0001 14.35 2 4340 <.0001 8.24 2 1776 .0003
Concentration-by-
time
88.82 1 4705 <.0001 45.41 1 4340 <.0001 25.68 1 1776 <.0001
Age 0.20 1 4705 a 2.56 1 4340 a 1.95 1 1776 a
Gender 2.29 1 4705 a 14.19 1 4340 .0002 0.83 1 1776 a
Cigarette smoking 2.76 1 4705 a 5.20 1 4340 .02 3.41 1 1776 a
Coffee drinking 2.10 1 4705 a 0.25 1 4340 a 0.16 1 1776 a
History of allergy 0.53 1 4705 a 0.23 1 4340 a 0.14 1 1776 a
aNot significant (P > .05).
Table 1. Demographic Characteristics of Schizophrenia Probands, Nonpsychotic First-Degree Relatives, and Healthy Controls.
Schizophrenia Probands Parents Siblings Healthy Controls
Multiplex
(N = 311)
Simplex
(N = 176)
Multiplex
(N = 180)
Simplex
(N = 260)
Multiplex
(N = 52)
Simplex
(N = 80) (N = 94)
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Age, years 37.7ab 8.0 31.6c 9.0 66.2ab 9.1 58.9c 9.5 39.8ab 10.2 32.1 10.7 34.1 10.1
Age at onset, years 22.1 6.1 21.2 7.0
N %d N %d N %d N %d N %d N %d N %
Male 202b 65.0 103 58.5 80 44.4 114 43.8 32 61.5 42 52.5 45 47.9
Cigarette smoking 123ab 39.9 48c 27.6 41ab 23.2 29 11.2 22ab 42.3 15 19.2 10 10.6
Coffee drinking 21b 6.8 17c 9.7 7b 4.0 19c 7.4 3b 5.8 12 15.4 21 22.3
History of allergy 7a 2.3 12 6.8 12 6.7 27c 10.4 2 3.8 5 6.3 2 2.1
aP <.05, multiplex versus simplex group by t test (for continuous variables) or v2 test (for categorical variables).
bP <.05, multiplex versus control group by t test or v2 test.
cP <.05, simplex versus control group by t test or v2 test.
dData were missing for some subjects, so percents were based on varying numbers.
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Profile of Niacin Flush Response
Table 2 summarizes the results of mixed-effects modeling
analyses comparing the flush response of different groups
across the concentrations and time lags of the niacin skin
test. For each of the comparisons among healthy controls
and the multiplex and simplex groups of probands, par-
ents, or siblings, respectively, 3-way group-concentration-
time interaction was insignificant and thus dropped from
subsequent analyses. Significant overall effects were
demonstrated for group, concentration, time, and their
pairwise 2-way interactions, whereas the effects of other
covariates were mostly not significant except for gender
and cigarette smoking when comparing parents with
healthy controls. Significant concentration-by-time inter-
action indicated that the increase of skin flushing over
time depended on applied AMN concentration. Further,
group-by-concentration and group-by-time interactions
indicated that the effect of genetic loading on niacin flush
response differed by applied AMN concentration and ob-
servation time. Hence, group differences for each of the
concentration-time combinations were depicted in figure
1 for examination in more detail.
The profiles of niacin flush response in schizophrenia
probands, their relatives, and healthy controls showed
that the flush response tended to become more intense
for both higher AMN concentration and longer time
lag (figure 1, see online supplementary figure 1 for a color
image). For the concentration of 0.001M, the flush scores
were generally approaching zero, and group differences
in flush response were not significant across time. There-
fore, the results of 0.001Mwere not shown in figure 1 (but
see in online supplementary figure 1). Indeed, most of the
subjects in any group (83%–98%) showed nonflush re-
sponse for this concentration even at 15 minutes (see
online supplementary figure 2).
For the remaining 2 concentrations of 0.01M and
0.1M, the reductions in mean flush scores for multiplex
families as compared with those for simplex ones were
more profound for 0.1M, with significant differences
in post hoc comparisons between the 2 groups (figure
1) and relatively large effect sizes across the 3 time points
(0.6–1.0 for probands, 0.9–1.3 for parents, and 0.7–1.0
for siblings). In contrast, for 0.01M, flush response scores
in multiplex and simplex families were comparable except
for lower mean flush score in parents frommultiplex fam-
ilies at 15minutes than in their counterparts from simplex
families. Compared with healthy controls, reduced flush
response in subjects from simplex families was more pro-
found for the concentration of 0.01M than that of 0.1M,
Fig. 1.Mean Niacin Flush Scores at 3 Time Points for 0.01M and
0.1M Concentrations of Aqueous Methyl Nicotinate in
Schizophrenia Probands, Nonpsychotic First-Degree Relatives,
and Healthy Controls. (a) Significant results were of post hoc
pairwise comparisons with Bonferroni correction following
significant group effect in multivariate mixed-effects or generalized
linear modeling analysis for each of the 9 concentration-time lag
combinations. A P value of less than .006 (.05 divided by 9) was
considered significant. (b)P< .006multiplex versus simplex group.
(c) P < .006 versus control group. A vertical bar indicates the
standard error of the mean flush score.
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with small to medium effect sizes across the 3 time points
(0.4–0.6 for probands, 0.2–0.5 for parents, and 0.2–0.5
for siblings). When multiplex families were compared
with healthy controls, subjects from multiplex families
had less skin flushing for both 0.01M and 0.1M, partic-
ularly at 10 and 15 minutes, with relatively large effect
sizes for these 2 time lags (1.0–1.3 for probands, 1.0–
1.4 for parents, and 0.6–1.0 for siblings).
Of note, for the setting in which the maximal flush re-
sponse was expected in the present study, ie, 15 minutes
following the application of 0.1M AMN skin patch,
a substantial proportion of probands (23%), parents
(27%), and siblings (19%) from multiplex families still
exhibited nonflush response, whereas complete erythem-
atous response could be seen in all of the healthy controls
and nearly all but 2%–5% of the subjects from simplex
families. The distributions of original flush response
scores, proportions of nonflush response, as well as the
mean and SD of the scores at 3 time points for 3
AMN concentrations by groups of subjects were demon-
strated in the online supplementary figure 2.
Discussion
To our knowledge, this is the first study comparing flush
response to niacin skin patch among families with differ-
ent genetic loading for schizophrenia. The results
revealed impaired niacin flush response in schizophrenia
patients and their relatives and that the impairment was
more pronounced in probands, parents, and siblings
from families with higher genetic loading for schizophre-
nia (multiplex families) than in their counterparts from
families with lower loading (simplex families). Further-
more, the optimal concentration of niacin for distinguish-
ing between multiplex and simplex families was 0.1M,
when a subgroup of subjects from multiplex families still
displayed little response to the strongest niacin stimula-
tion for this study.
The present study found significant differences by
means of collecting a sample size with adequate power
to discriminate between subjects with different genetic
loading for schizophrenia38,39 and adopting strategies
to address methodological concerns such as personal
interviews or obtaining family history information using
validated tool for diagnosing relatives and controlling for
potential confounders.40 In contrast, one previous study
compared flush response to oral niacin between schizo-
phrenia patients with positive family history and those
without,6 and the insignificant result in that study could
be attributed to insufficient power (33 schizophrenia
patients in total) and other methodological problems re-
lated to subtyping schizophrenia using family history.40
An important feature of this study is that a wide range
of AMN concentrations and time lags were examined.
The finding that group differences varied with different
concentration-time combinations is worthy of discussion.
First, schizophrenia probands and their relatives from
multiplex families consistently showed less skin flushing
than their counterparts from simplex families and healthy
controls for 0.1M. Furthermore, a significant proportion
of subjects frommultiplex families still presented with lit-
tle skin flushing in the setting the maximal response was
expected. Second, subjects from simplex families tended
to show less skin flushing than healthy controls for
0.01M, with significant difference across time found be-
tween healthy controls and probands but not their rela-
tives. However, simplex families did not differ from
healthy controls for 0.1M, and this could be due to the
ceiling of skin flush response in both groups for this con-
centration. Therefore, simplex families differed from
healthy controls in the distributions of flush response, in-
stead of the maximal response, and this finding was con-
sistent with a previous study.14 Third, the AMN
concentrations of 0.1M and 0.01M characterized the
group differences in niacin flush response better than
0.001M, and this finding was consistent with our previous
report that flush scores data obtained using 0.1M and
0.01M yielded the greatest estimated heritability and re-
currence risk ratios.23 Thus, stimulation using 0.1M and
0.01M of AMN would provide more variations in skin
flush response, whereas 0.001M could not evoke mean-
ingful flushing among subjects. These findings imply
that future genetic studies in schizophrenia should use ni-
acin stimulation with these 2 concentrations of 0.1M and
0.01M to better discriminate between subjects’ flush
response.
Another feature of this study is that many potential
confounders were controlled for in the analyses. Unlike
the reported influence of age and gender on the flush re-
sponse to niacin skin patch in one previous study,41 we
found that the effects of age, coffee drinking, and history
of allergy were not significant, a finding consistent with
several studies on niacin skin test,14,15,17 and that the
effects of gender and cigarette smoking were significant
only when comparing parents with healthy controls. Nev-
ertheless, our finding of the genetic loading effect on ni-
acin flush response was robust after accounting for these
covariates.
Whether to include those disorders thought to be ge-
netically linked to schizophrenia such as schizotypal,
schizoid, or paranoid personality disorders in the defini-
tion of family type might influence the study results.29
This influence was assessed in this study by regrouping
or excluding those simplex families having a sibling or
a parent diagnosed with these personality disorders, re-
spectively, and the main results remained unchanged.
Our findings have important implications on the use of
niacin skin patch test in genetic studies of schizophrenia.
First, our results, together with our previous finding of
family aggregation,23 suggest that abnormal flush re-
sponse to niacin may be an endophenotype for schizo-
phrenia.42 The finding that only a subgroup but not all
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of the patients showed abnormal skin flushing implies
that impaired niacin flush response might be an endophe-
notype rather than a diagnostic marker for schizophre-
nia. Schizophrenia patients and their relatives who
presented with deficits in niacin flush response might
share some specific pathophysiological characteristics
or genotypes responsible for vulnerability to schizophre-
nia and thus could be an etiologically homogenous group
for genetic linkage or association study. However, further
studies are needed to examine whether the abnormal
niacin flush response is independent of disease states
and associated with certain candidate genes or gene
regions of schizophrenia. In addition, the use of niacin
flush response as an endophenotype may also be applied
in imaging, cognition, or treatment studies on schizo-
phrenia. For example, a recent study reported the asso-
ciation of peripheral niacin flush response with central
metabolism by showing negative correlation between
skin flushing and the levels of cerebral energymetabolism
measured by 31-phosphorus magnetic resonance spec-
troscopy in male schizophrenia patients.43
Second, a further understanding of the biochemical
processes underlying the abnormal niacin flush response
and related genetic regulations may lead to new direc-
tions for etiological research of schizophrenia. Because
the niacin flush response has been demonstrated to be
mediated by prostaglandin, particularly prostaglandin
D2,
2,3 the underlying mechanism of the abnormal skin re-
sponse to niacin might involve any step in the process of
prostaglandin signaling.44 Prostaglandins are derived
from metabolism of membrane lipids, and disturbed lip-
ids metabolism in both central and peripheral tissues was
repeatedly shown in schizophrenia.45,46 One previous
study had shown the usefulness of niacin skin test in iden-
tifying a gene polymorphism related to a key enzyme in
lipids metabolism and further used this marker in genetic
association study on schizophrenia.47
Finally, the niacin skin test may be used as a research
tool to test new etiological hypotheses of schizophrenia
with an emphasis on the inflammatory process. For ex-
ample, a novel theory of schizophrenia has reviewed the
evidence that inflammatory vascular disease of the brain
can lead to psychosis and hypothesized schizophrenia as
a genetically mediated central nervous system microvas-
cular inflammation disease.48 Because the impairment in
flush response to niacin might be one peripheral marker
of a centrally as well as systemically disturbed inflamma-
tory process, the niacin skin test might be used as a screen-
ing tool for abnormal inflammatory reaction and related
aberrant genetic regulations.
The study has several limitations. First, a mean age of
32 years in siblings from simplex families in our sample
implied that some of them had not passed through the age
of risk and this might lead to misclassification of family
type. Second, we directly interviewed only half of alive
first-degree relatives from simplex families, and, for those
who were not directly interviewed, a failure to diagnose
schizophrenia in affected relatives might cause misclassi-
fication of family type, too. Nevertheless, we used a val-
idated tool on collecting family history information to
reduce false negatives. Furthermore, above misclassifica-
tions tended to categorize multiplex case as simplex one
and thus would diminish rather than increase differences
in niacin flush response between the 2 groups. Third,
most of the patients with schizophrenia in this study
were receiving medication treatment, and this might in-
fluence our results because some studies have reported
alteration of flush response to niacin by antipsychotic
treatment.19,49 However, most of the previous studies
found that medication status did not influence niacin
flush response,10,14,15,17 and our findings in nonpsychotic
relatives in addition to probands further suggested niacin
flush response as a genetic trait independent of medica-
tion or disease status.
In summary, impaired flush response to topical niacin
was associated with genetic loading for schizophrenia, in-
dicated by more blunted skin response in probands,
parents, and siblings from multiplex families than their
counterparts from simplex families. In 3-by-3 combina-
tions of niacin concentration and time lag, the differen-
tiation between subjects with different genetic loading
was better revealed using 0.1M concentration of niacin
skin patch than 0.01M or 0.001M. Heterogeneity is indi-
cated by the finding that a subgroup of patients and their
relatives from multiplex families still displayed blunted
skin response in the setting when subjects from simplex
families or healthy controls exhibited complete erythema.
Our findings support that abnormal niacin-induced skin
flush response is a vulnerability trait for schizophrenia
and might be useful in future genetic dissection of
schizophrenia.
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